Correction to: On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF
In the article by Fordyce et al, “On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF,” which published in the July 5, 2016, issue of the journal (Circulation. 2016;134:37–47. DOI: 10.1161/CIRCULATIONAHA.116.021890), a correction is needed.
On page 38, under the section, Renal Function and Dose Assignment, a number was omitted from the first sentence. The sentence should read:
“The study protocol required that patients receive a minimum of 4 serum creatinine measurements: at screening, 24 weeks after randomization, 52 weeks after randomization, and the end of the study or at early study drug discontinuation.”
This correction has been made to the current online version of the article, which is available at http://circ.ahajournals.org/lookup/doi/10.1161/CIRCULATIONAHA.116.021890.
Circulation is available at http://circ.ahajournals.org.
- © 2016 American Heart Association, Inc.